User:Devon Cosgrove/sandbox
Copied From:
[edit]
Management
[edit]The management of ADHD typically involves counseling or the use of medication either alone or in combination. ((While treatment may improve long-term outcomes, it has not show to only diminish its effects)).[1] Medications used include stimulants, atomoxetine, alpha-2 adrenergic receptor agonists, and sometimes antidepressants.[2][3] ADHD stimulants also improve persistence and task performance in children with ADHD.[4][5] In those who have trouble focusing on long-term rewards, a large amount of positive reinforcement improves task performance (Gaskins?).[5] In the classroom
There is good evidence for the use of behavioral therapies in ADHD and they are the recommended first line treatment in those who have mild symptoms or are preschool-aged.[6][7] Psychological therapies used include: psychoeducational input, behavior therapy, cognitive behavioral therapy (CBT), interpersonal psychotherapy, family therapy, school-based interventions, social skills training, behavioral peer intervention, organization training,[8] parent management training,[9] and neurofeedback.[10] Parent training may improve a number of behavioral problems including oppositional and noncompliant behaviours.[11] It is unclear if neurofeedback is useful.[12]
There is little high quality research on the effectiveness of family therapy for ADHD, but the evidence that exists shows that it is similar to community care and better than a placebo ((Australian review).[13] Several ADHD specific support groups exist as informational sources and may help families cope with ADHD.[14]
(((( studies within the last decade may suggest that ADHD can initially be diagnosed as depression and other mood disorders before being understood to be ADHD.)) ((Seeking counseling for help in)) social skills, behavioral modification, ((critical thinking)) and medication may have some limited beneficial effects to the individual. ((Should troubling behavior and feelings arise, it is important that family, friends and counselors help the individual to seek help. It has been found to be a)) important factor in reducing later psychological problems, such as major depression, criminality, school failure, and substance abuse disorders is formation of friendships with people who are not involved in delinquent activities.[15] (have sources dateing to 2010 so what is different about source in 2005?)
((needs it own section heading))
Regular physical exercise, particularly aerobic exercise, is an effective add-on treatment for ADHD in children and adults, particularly when combined with stimulant medication, although the best intensity and type of aerobic exercise for improving symptoms are not currently known.[16][17][18] In particular, the long-term effects of regular aerobic exercise in ADHD individuals (can) include better behavior and motor abilities, improved executive functions (including attention, inhibitory control, and planning, among other cognitive domains),((long sentence)) faster information processing speed, and better memory.[16][17][18] Parent-teacher ratings of behavioral and socio-emotional outcomes in response to regular aerobic exercise include: better overall function, reduced ADHD symptoms, better self-esteem, reduced levels of anxiety and depression, fewer somatic complaints, better academic and classroom behavior, and improved social behavior.[16] Exercising while on stimulant medication ??augments?? the effect of stimulant medication on executive function.[16] It is believed It has been demonstrated and perceived that these short-term effects of exercise are mediated by an increased abundance of synaptic dopamine and norepinephrine in the brain.[16]
Medication
[edit](image ritalin is promoting the drug brand)
Stimulant medications are the pharmaceutical treatment of choice.[19][20] (2009) (2011) They have at least some effect on symptoms in the short term in about 80% of people.[21](2013 is not enough for this statement to be credited tit could advance since then greatly - 2018) Methylphenidate appears to improve symptoms as reported by teachers and parents.[22] (( Methylphenidate is a specific compound use in Ritalin. it does not mention others like phenethylamine used is drugs like Adderall. Lisdexamfetamine in Vyvanse. Dextroamphetamine used in Concerta. It is pushing Ritalin)) Stimulants may also reduce the risk of unintentional injuries in children with ADHD.[23] (feels out of place)
There are a number of non-stimulant medications, such as atomoxetine, bupropion, guanfacine, and clonidine that may be used as alternatives, or added to stimulant therapy.[19][24] ((The recent no good studies comparing the various medications have found to be poor determinants)); however, they ((can)) appear more or less equal with in respect to side effects.[25] Stimulants appear to improve academic performance while atomoxetine does not.[26] (2013) Atomoxetine, due to its lack of addiction liability, may be preferred in those who are at risk of recreational or compulsive stimulant use. ((liability what to what?))[27](2010) There is little evidence on the effects of medication on social behaviors. (will find evidence to show this has changed)) [25] As of June 2015[update], the long-term effects of ADHD medication have yet to be fully determined.[28][29] Magnetic resonance imaging studies suggest that long-term treatment with amphetamine ((randomly pulls in word amphetamine in this category with no prior statement of it)) or methylphenidate decreases abnormalities in brain structure and function found in subjects with ADHD.[30][31][32]
Guidelines on when to use medications vary by country, with the United Kingdom's National Institute for Health and Care Excellence recommending use for children only in severe cases, though for adults medication is a first-line treatment. (made two sentences) While most United States guidelines recommend medications in most age groups.[33] Medications are not recommended for preschool children.((Why?))[9][34] Underdosing of stimulants may ((can)) occur and result in a lack of response or later loss of effectiveness.[35] This is particularly common in adolescents and adults as approved dosing is based on school-aged children, causing some practitioners to use weight based or benefit based off-label dosing instead.[36][37][38] ((could add about periods and male school children dosing typically applied based on the source I have))
While stimulants and atomoxetine((?)) are usually safe, there are side-effects and contraindications to their use.(give more examples then just one)[19] A large overdose on ADHD stimulants is commonly associated with symptoms such as stimulant psychosis and mania;[39] although very rare,(.) at therapeutic doses these events(example) appear to occur in approximately 0.1% of individuals within the first several weeks after starting amphetamine or methylphenidate therapy.[39][40][41] Administration of an antipsychotic medication has been found to effectively resolve ((help to treat)) the symptoms of acute amphetamine psychosis.[39] Regular monitoring has been recommended in those on long-term treatment.[42] Stimulant therapy should be stopped periodically to assess continuing need for medication, decrease possible growth delay, and reduce tolerance.[43][44] Long-term misuse of stimulant medications at doses above the normal dose, in the therapeutic range for ADHD treatment, is associated with addiction and dependence.[45][46] Untreated ADHD, however, is also associated with elevated risk of substance use disorders and conduct disorders.[45] The use of stimulants appears to either reduce this risk or have no effect on it.[27][28][45]((2008)) The safety of these medications in pregnancy is unclear.[47] ((2006))
Attention Deficit Hyperactivity Disorder
[edit]My Additions:
Neurofeedback (have to check biofeedback or biofeedback)
[edit]Neurofeedback is the recording of brainwaves which interprets them and turns it into biofeedback, a process where an individual learns to take control of their brainwave patterns in the hopes of having that individual control their brain states. {cite} The idea of Neurofeedback has been around since the1970’s. Since then, research into the field has improved, especially in regards to how it affects individuals with ADD/ADHD. Neurofeedback seeks to isolate four different brainwave patterns: Beta, Alpha, Theta, and Delta to lessen or improve the areas related to controlling attention, behavior, and or emotions. Over the course of as many as 40-50 sessions go on average an upwards of 40 to 60 minutes the individual will be asked to do a series of tasks that will be performed through their brainwaves. Tasks include listen to audio tones, play a video game or read via a screen, are trying to encourage the brain to manage it's thoughts. After Neurofeedback therapy, individuals IQ has been recorded to increase by 9-12 points
When the process of Neurofeedback treatment starts, electrodes are expected to be placed on the scalp and earlobes in the hopes of determining and evaluating the patterns that are coming from the brain.
EEG is considered a non invasive treatment since it uses a tiny electromagnetic signal, rather than a direct voltage or current (change word) applied to the patient. In order to recondition and retrain the brain wave patterns, it is required to understand that specific brainwaves are often linked to problems in consecration, memory, controlling impulses and moods, hyperactivity. ( not sure how to segway) Beta waves are often the smaller faster brain waves associated with intellectual activity and outwardly focused concentration. Alpha waves are much larger and slower and connected to the brains relaxation and disengaged behaviors. Theta waves influence mental inefficiency, creating a "spacy" state in individuals. Lastly Delta waves are the slowest high amplitude waves out of the four, and are the waves that are equated with learning disabilities and are experienced when asleep. When focusing on ADD/ADHD patients brainwaves, most technicians tend to see excessively slow brain waves as a common occurrence.
Those who adopt this method often find it more important than treating the widely accepted practice of treating the “chemical imbalance” with medication. 80% of clients who use Neurofeedback as a treatment, can substantially improve the symptoms of ADD. Some on the side effects patients may feel once they begin treatment is tiredness, lack of focus, anxious, headaches, difficulty falling asleep or agitation and irritability. However, most of these side effects often pass as treatments continue. These changes are often maintain comparable improvements in attention and concentration in juxtaposition to taking Ritalin. Long-term safety of the medications used in the treatment of ADD/ADHA treatment, evidence from studies, often lacks the information on the effect that drug treatment improves academic performance or risky behaviors on long term basis, in adolescents or adults. After only three months on Ritalin, 100% of children experience chromosomal aberrations which could increase cancer risk, not unlike adult methamphetamine users (cite). Not yet taught in most medical schools or psychology graduate programs, it is considered of the utmost importance to seek treatment with highly trained professionals, rather then seek at-home treatment. If self treatment is improperly applied, it maybe more detrimental to the patient then helpful.
(should I include) families where member had ADHS / cost of health care / averaged $1,288 per year higher / comparison ADD was not present /combined with indirect costs would be $5,542
This is a user sandbox of Devon Cosgrove. You can use it for testing or practicing edits. This is not the sandbox where you should draft your assigned article for a dashboard.wikiedu.org course. To find the right sandbox for your assignment, visit your Dashboard course page and follow the Sandbox Draft link for your assigned article in the My Articles section. |
- ^ Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, Arnold LE (4 September 2012). "A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment". BMC Med. 10: 99. doi:10.1186/1741-7015-10-99. PMC 3520745. PMID 22947230.
{{cite journal}}
: CS1 maint: unflagged free DOI (link) - ^ Wilens TE, Spencer TJ (September 2010). "Understanding attention-deficit/hyperactivity disorder from childhood to adulthood". Postgrad Med. 122 (5): 97–109. doi:10.3810/pgm.2010.09.2206. PMC 3724232. PMID 20861593.
- ^ Bidwell LC, McClernon FJ, Kollins SH (August 2011). "Cognitive enhancers for the treatment of ADHD". Pharmacol. Biochem. Behav. 99 (2): 262–274. doi:10.1016/j.pbb.2011.05.002. PMC 3353150. PMID 21596055.
- ^ Malenka RC, Nestler EJ, Hyman SE (2009). "Chapters 10 and 13". In Sydor A, Brown RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 266, 315, 318–323. ISBN 978-0-07-148127-4.
Early results with structural MRI show thinning of the cerebral cortex in ADHD subjects compared with age-matched controls in prefrontal cortex and posterior parietal cortex, areas involved in working memory and attention.
- ^ a b Modesto-Lowe V, Chaplin M, Soovajian V, Meyer A (2013). "Are motivation deficits underestimated in patients with ADHD? A review of the literature". Postgrad Med. 125 (4): 47–52. doi:10.3810/pgm.2013.07.2677. PMID 23933893. S2CID 24817804.
Behavioral studies show altered processing of reinforcement and incentives in children with ADHD. These children respond more impulsively to rewards and choose small, immediate rewards over larger, delayed incentives. Interestingly, a high intensity of reinforcement is effective in improving task performance in children with ADHD. Pharmacotherapy may also improve task persistence in these children. ... Previous studies suggest that a clinical approach using interventions to improve motivational processes in patients with ADHD may improve outcomes as children with ADHD transition into adolescence and adulthood.
- ^ Fabiano GA, Pelham WE, Coles EK, Gnagy EM, Chronis-Tuscano A, O'Connor BC (March 2009). "A meta-analysis of behavioral treatments for attention-deficit/hyperactivity disorder". Clin Psychol Rev. 29 (2): 129–140. doi:10.1016/j.cpr.2008.11.001. PMID 19131150.
- ^ Kratochvil CJ, Vaughan BS, Barker A, Corr L, Wheeler A, Madaan V (March 2009). "Review of pediatric attention deficit/hyperactivity disorder for the general psychiatrist". Psychiatr. Clin. North Am. 32 (1): 39–56. doi:10.1016/j.psc.2008.10.001. PMID 19248915.
- ^ Evans, SW; Owens, JS; Bunford, N (2014). "Evidence-based psychosocial treatments for children and adolescents with attention-deficit/hyperactivity disorder". Journal of Clinical Child and Adolescent Psychology. 43 (4): 527–51. doi:10.1080/15374416.2013.850700. PMC 4025987. PMID 24245813.
- ^ a b National Collaborating Centre for Mental Health (2009). Attention Deficit Hyperactivity Disorder: Diagnosis and Management of ADHD in Children, Young People and Adults. NICE Clinical Guidelines. Vol. 72. Leicester: British Psychological Society. ISBN 978-1-85433-471-8. Archived from the original on 13 January 2016 – via NCBI Bookshelf.
- ^ Arns M, de Ridder S, Strehl U, Breteler M, Coenen A (July 2009). "Efficacy of neurofeedback treatment in ADHD: the effects on inattention, impulsivity and hyperactivity: a meta-analysis". Clin EEG Neurosci. 40 (3): 180–189. doi:10.1177/155005940904000311. PMID 19715181. S2CID 6034033.
- ^ Daley, D; Van Der Oord, S; Ferrin, M; Cortese, S; Danckaerts, M; Doepfner, M; Van den Hoofdakker, BJ; Coghill, D; Thompson, M; Asherson, P; Banaschewski, T; Brandeis, D; Buitelaar, J; Dittmann, RW; Hollis, C; Holtmann, M; Konofal, E; Lecendreux, M; Rothenberger, A; Santosh, P; Simonoff, E; Soutullo, C; Steinhausen, HC; Stringaris, A; Taylor, E; Wong, ICK; Zuddas, A; Sonuga-Barke, EJ (30 October 2017). "Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 59 (9): 932–947. doi:10.1111/jcpp.12825. hdl:11343/293788. PMID 29083042. S2CID 31044370.
- ^ Cortese, S; Ferrin, M; Brandeis, D; Holtmann, M; Aggensteiner, P; Daley, D; Santosh, P; Simonoff, E; Stevenson, J; Stringaris, A; Sonuga-Barke, EJ; European ADHD Guidelines Group, (EAGG). (June 2016). "Neurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials". Journal of the American Academy of Child and Adolescent Psychiatry. 55 (6): 444–55. doi:10.1016/j.jaac.2016.03.007. PMID 27238063.
- ^ Bjornstad G, Montgomery P (2005). Bjornstad GJ (ed.). "Family therapy for attention-deficit disorder or attention-deficit/hyperactivity disorder in children and adolescents". Cochrane Database Syst Rev (2): CD005042. doi:10.1002/14651858.CD005042.pub2. PMID 15846741.
- ^ Turkington, Carol; Harris, Joseph (2009). "attention deficit hyperactivity disorder (ADHD)". The Encyclopedia of the Brain and Brain Disorders. Infobase Publishing. p. 47. ISBN 978-1-4381-2703-3 – via Google Books.
- ^ Mikami, Amori Yee (June 2010). "The importance of friendship for youth with attention-deficit/hyperactivity disorder". Clin Child Fam Psychol Rev. 13 (2): 181–98. doi:10.1007/s10567-010-0067-y. PMC 2921569. PMID 20490677.
- ^ a b c d e Den Heijer AE, Groen Y, Tucha L, Fuermaier AB, Koerts J, Lange KW, Thome J, Tucha O (July 2016). "Sweat it out? The effects of physical exercise on cognition and behavior in children and adults with ADHD: a systematic literature review". J. Neural. Transm. (Vienna). 124 (Suppl 1): 3–26. doi:10.1007/s00702-016-1593-7. PMC 5281644. PMID 27400928.
Beneficial chronic effects of cardio exercise were found on various functions as well, including executive functions, attention and behavior.
- ^ a b Kamp CF, Sperlich B, Holmberg HC (July 2014). "Exercise reduces the symptoms of attention-deficit/hyperactivity disorder and improves social behaviour, motor skills, strength and neuropsychological parameters". Acta Paediatr. 103 (7): 709–714. doi:10.1111/apa.12628. PMID 24612421. S2CID 45881887. Archived from the original on 21 March 2015. Retrieved 14 March 2015.
We may conclude that all different types of exercise ... attenuate the characteristic symptoms of ADHD and improve social behaviour, motor skills, strength and neuropsychological parameters without any undesirable side effects. Available reports do not reveal which type, intensity, duration and frequency of exercise is most effective
- ^ a b Rommel AS, Halperin JM, Mill J, Asherson P, Kuntsi J (September 2013). "Protection from genetic diathesis in attention-deficit/hyperactivity disorder: possible complementary roles of exercise". J. Am. Acad. Child Adolesc. Psychiatry. 52 (9): 900–910. doi:10.1016/j.jaac.2013.05.018. PMC 4257065. PMID 23972692.
The findings from these studies provide some support for the notion that exercise has the potential to act as a protective factor for ADHD.
- ^ a b c Wigal SB (2009). "Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults". CNS Drugs. 23 Suppl 1: 21–31. doi:10.2165/00023210-200923000-00004. PMID 19621975. S2CID 11340058.
- ^ Castells X, Ramos-Quiroga JA, Bosch R, Nogueira M, Casas M (2011). Castells X (ed.). "Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults". Cochrane Database Syst. Rev. (6): CD007813. doi:10.1002/14651858.CD007813.pub2. PMID 21678370.
- ^ Parker J, Wales G, Chalhoub N, Harpin V (September 2013). "The long-term outcomes of interventions for the management of attention-deficit hyperactivity disorder in children and adolescents: a systematic review of randomized controlled trials". Psychol. Res. Behav. Manag. 6: 87–99. doi:10.2147/PRBM.S49114. PMC 3785407. PMID 24082796.
Results suggest there is moderate-to-high-level evidence that combined pharmacological and behavioral interventions, and pharmacological interventions alone can be effective in managing the core ADHD symptoms and academic performance at 14 months. However, the effect size may decrease beyond this period. ... Only one paper examining outcomes beyond 36 months met the review criteria. ... There is high level evidence suggesting that pharmacological treatment can have a major beneficial effect on the core symptoms of ADHD (hyperactivity, inattention, and impulsivity) in approximately 80% of cases compared with placebo controls, in the short term.22
{{cite journal}}
: CS1 maint: unflagged free DOI (link) - ^ Storebø, OJ; Ramstad, E; Krogh, HB; Nilausen, TD; Skoog, M; Holmskov, M; Rosendal, S; Groth, C; Magnusson, FL; Moreira-Maia, CR; Gillies, D; Buch Rasmussen, K; Gauci, D; Zwi, M; Kirubakaran, R; Forsbøl, B; Simonsen, E; Gluud, C (25 November 2015). "Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)". The Cochrane Database of Systematic Reviews. 2016 (11): CD009885. doi:10.1002/14651858.CD009885.pub2. PMC 8763351. PMID 26599576.
- ^ Ruiz-Goikoetxea, Maite; Cortese, Samuele; Aznarez-Sanado, Maite; Magallón, Sara; Alvarez Zallo, Noelia; Luis, Elkin O.; de Castro-Manglano, Pilar; Soutullo, Cesar; Arrondo, Gonzalo (2018). "Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: A systematic review and meta-analysis". Neuroscience & Biobehavioral Reviews. 84: 63–71. doi:10.1016/j.neubiorev.2017.11.007. ISSN 0149-7634. PMID 29162520. S2CID 9313984.
- ^ Childress, A. C.; Sallee, F. R. (2012). "Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder". Drugs of Today (Barcelona, Spain: 1998). 48 (3): 207–217. doi:10.1358/dot.2012.48.3.1750904. ISSN 1699-3993. PMID 22462040.
- ^ a b McDonagh MS, Peterson K, Thakurta S, Low A (December 2011). "Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder". United States Library of Medicine. PMID 22420008. Archived from the original on 31 August 2016.
{{cite journal}}
: Cite journal requires|journal=
(help) - ^ Prasad V, Brogan E, Mulvaney C, Grainge M, Stanton W, Sayal K (April 2013). "How effective are drug treatments for children with ADHD at improving on-task behaviour and academic achievement in the school classroom? A systematic review and meta-analysis". Eur Child Adolesc Psychiatry. 22 (4): 203–216. doi:10.1007/s00787-012-0346-x. PMID 23179416. S2CID 7147886.
- ^ a b Kooij, SJ; Bejerot, S; Blackwell, A; Caci, H; et al. (2010). "European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD". BMC Psychiatry. 10: 67. doi:10.1186/1471-244X-10-67. PMC 2942810. PMID 20815868.
{{cite journal}}
: CS1 maint: unflagged free DOI (link) - ^ a b Kiely B, Adesman A (June 2015). "What we do not know about ADHD… yet". Curr. Opin. Pediatr. 27 (3): 395–404. doi:10.1097/MOP.0000000000000229. PMID 25888152. S2CID 39004402.
In addition, a consensus has not been reached on the optimal diagnostic criteria for ADHD. Moreover, the benefits and long-term effects of medical and complementary therapies for this disorder continue to be debated. These gaps in knowledge hinder the ability of clinicians to effectively recognize and treat ADHD.
- ^ Hazell P (July 2011). "The challenges to demonstrating long-term effects of psychostimulant treatment for attention-deficit/hyperactivity disorder". Current Opinion in Psychiatry. 24 (4): 286–290. doi:10.1097/YCO.0b013e32834742db. PMID 21519262. S2CID 21998152.
- ^ Hart H, Radua J, Nakao T, Mataix-Cols D, Rubia K (February 2013). "Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects". JAMA Psychiatry. 70 (2): 185–198. doi:10.1001/jamapsychiatry.2013.277. PMID 23247506.
- ^ Spencer TJ, Brown A, Seidman LJ, Valera EM, Makris N, Lomedico A, Faraone SV, Biederman J (September 2013). "Effect of psychostimulants on brain structure and function in ADHD: a qualitative literature review of magnetic resonance imaging-based neuroimaging studies". J. Clin. Psychiatry. 74 (9): 902–917. doi:10.4088/JCP.12r08287. PMC 3801446. PMID 24107764.
- ^ Frodl T, Skokauskas N (February 2012). "Meta-analysis of structural MRI studies in children and adults with attention deficit hyperactivity disorder indicates treatment effects". Acta Psychiatrica Scand. 125 (2): 114–126. doi:10.1111/j.1600-0447.2011.01786.x. PMID 22118249. S2CID 25954331.
Basal ganglia regions like the right globus pallidus, the right putamen, and the nucleus caudatus are structurally affected in children with ADHD. These changes and alterations in limbic regions like ACC and amygdala are more pronounced in non-treated populations and seem to diminish over time from child to adulthood. Treatment seems to have positive effects on brain structure.
- ^ "Canadian ADHD Practice Guidelines" (PDF). Canadian ADHD Alliance. Retrieved 4 February 2011.
- ^ Greenhill LL, Posner K, Vaughan BS, Kratochvil CJ (April 2008). "Attention deficit hyperactivity disorder in preschool children". Child and Adolescent Psychiatric Clinics of North America. 17 (2): 347–366, ix. doi:10.1016/j.chc.2007.11.004. PMID 18295150.
- ^ Stevens, Jonathan R.; Wilens, Timothy E.; Stern, Theodore A. (2013). "Using Stimulants for Attention-Deficit/Hyperactivity Disorder: Clinical Approaches and Challenges". The Primary Care Companion for CNS Disorders. 15 (2). doi:10.4088/PCC.12f01472. ISSN 2155-7772. PMC 3733520. PMID 23930227.
- ^ Young, Joel L. (2010). "Individualizing Treatment for Adult ADHD: An Evidence-Based Guideline". Medscape. Archived from the original on 8 May 2015. Retrieved 19 June 2016.
- ^ Biederman, Joseph (2003). "New-Generation Long-Acting Stimulants for the Treatment of Attention-Deficit/Hyperactivity Disorder". Medscape. Archived from the original on 7 December 2003. Retrieved 19 June 2016.
As most treatment guidelines and prescribing information for stimulant medications relate to experience in school-aged children, prescribed doses for older patients are lacking. Emerging evidence for both methylphenidate and Adderall indicate that when weight-corrected daily doses, equipotent with those used in the treatment of younger patients, are used to treat adults with ADHD, these patients show a very robust clinical response consistent with that observed in pediatric studies. These data suggest that older patients may require a more aggressive approach in terms of dosing, based on the same target dosage ranges that have already been established – for methylphenidate, 1–1.5–2 mg/kg/day, and for D,L-amphetamine, 0.5–0.75–1 mg/kg/day....
In particular, adolescents and adults are vulnerable to underdosing, and are thus at potential risk of failing to receive adequate dosage levels. As with all therapeutic agents, the efficacy and safety of stimulant medications should always guide prescribing behavior: careful dosage titration of the selected stimulant product should help to ensure that each patient with ADHD receives an adequate dose, so that the clinical benefits of therapy can be fully attained. - ^ Kessler, S. (1996). "Drug therapy in attention-deficit hyperactivity disorder". Southern Medical Journal. 89 (1): 33–38. doi:10.1097/00007611-199601000-00005. ISSN 0038-4348. PMID 8545689. S2CID 12798818.
- ^ a b c Shoptaw SJ, Kao U, Ling W (January 2009). Shoptaw SJ, Ali R (ed.). "Treatment for amphetamine psychosis". Cochrane Database Syst. Rev. (1): CD003026. doi:10.1002/14651858.CD003026.pub3. PMC 7004251. PMID 19160215.
A minority of individuals who use amphetamines develop full-blown psychosis requiring care at emergency departments or psychiatric hospitals. In such cases, symptoms of amphetamine psychosis commonly include paranoid and persecutory delusions as well as auditory and visual hallucinations in the presence of extreme agitation. More common (about 18%) is for frequent amphetamine users to report psychotic symptoms that are sub-clinical and that do not require high-intensity intervention ...
About 5–15% of the users who develop an amphetamine psychosis fail to recover completely (Hofmann 1983) ...
Findings from one trial indicate use of antipsychotic medications effectively resolves symptoms of acute amphetamine psychosis. - ^ "Adderall XR Prescribing Information" (PDF). United States Food and Drug Administration. Shire US Inc. December 2013. Archived (PDF) from the original on 30 December 2013. Retrieved 30 December 2013.
Treatment-emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without prior history of psychotic illness or mania can be caused by stimulants at usual doses. ... In a pooled analysis of multiple short-term, placebo controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.
- ^ Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R (February 2009). "Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children". Pediatrics. 123 (2): 611–616. doi:10.1542/peds.2008-0185. PMID 19171629. S2CID 22391693.
- ^ Kraemer M, Uekermann J, Wiltfang J, Kis B (July 2010). "Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature". Clin Neuropharmacol. 33 (4): 204–6. doi:10.1097/WNF.0b013e3181e29174. PMID 20571380. S2CID 34956456.
- ^ van de Loo-Neus GH, Rommelse N, Buitelaar JK (August 2011). "To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended?". Eur Neuropsychopharmacol. 21 (8): 584–599. doi:10.1016/j.euroneuro.2011.03.008. PMID 21530185. S2CID 30068561.
- ^ Ibrahim, Kinda; Donyai, Parastou (2015). "Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades". Journal of Attention Disorders. 19 (7): 551–568. doi:10.1177/1087054714548035. ISSN 1557-1246. PMID 25253684. S2CID 19949563. Archived (PDF) from the original on 30 June 2016.
- ^ a b c Malenka, RC; Nestler, EJ; Hyman, SE (2009). Sydor, A; Brown, RY (eds.). Molecular Neuropharmacology: A Foundation for Clinical Neuroscience (2nd ed.). New York: McGraw-Hill Medical. pp. 323, 368. ISBN 978-0-07-148127-4.
supervised use of stimulants at therapeutic doses may decrease risk of experimentation with drugs to self-medicate symptoms. Second, untreated ADHD may lead to school failure, peer rejection, and subsequent association with deviant peer groups that encourage drug misuse. ... amphetamines and methylphenidate are used in low doses to treat attention deficit hyperactivity disorder and in higher doses to treat narcolepsy (Chapter 12). Despite their clinical uses, these drugs are strongly reinforcing, and their long-term use at high doses is linked with potential addiction
- ^ Oregon Health & Science University (2009). "Black box warnings of ADHD drugs approved by the US Food and Drug Administration". Portland, Oregon: United States National Library of Medicine. Archived from the original on 8 September 2017. Retrieved 17 January 2014.
- ^ Ashton H, Gallagher P, Moore B (September 2006). "The adult psychiatrist's dilemma: psychostimulant use in attention deficit/hyperactivity disorder". J. Psychopharmacol. (Oxford). 20 (5): 602–610. doi:10.1177/0269881106061710. PMID 16478756. S2CID 32073083. Archived from the original on 15 August 2009.